Patents by Inventor Seong Jun Yoon

Seong Jun Yoon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210283202
    Abstract: The present invention relates to a Myoviridae bacteriophage Esc-COP-14 (Accession number: KCTC 13528BP) isolated from nature, and characterized by having the ability to specifically kill Escherichia coli and having the genome represented by SEQ. ID. NO: 1, and to a method for preventing and treating the infection of pathogenic Escherichia coli using the composition comprising Myoviridae bacteriophage Esc-COP-14 as an active ingredient.
    Type: Application
    Filed: June 7, 2019
    Publication date: September 16, 2021
    Inventors: Seong Jun Yoon, Soo Youn Jun, Jee Soo Son, Hyoung Rok Paik, Hyun Joo Lee, Sang Hyeon Kang
  • Publication number: 20210161977
    Abstract: The present invention relates to a Siphoviridae bacteriophage Str-SUP-1 (Accession number: KCTC 13514BP) isolated from nature and characterized by having the ability to kill Streptococcus suis and having the genome represented by SEQ ID NO: 1, and a method for preventing and treating diseases caused by Streptococcus suis using the composition containing the Siphoviridae bacteriophage Str-SUP-1 as an active ingredient.
    Type: Application
    Filed: May 31, 2019
    Publication date: June 3, 2021
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Eun Ji Lee, Sang Hyeon Kang
  • Publication number: 20210161978
    Abstract: The present invention relates to a Siphoviridae bacteriophage Str-SUP-3 (Accession number: KCTC 13516BP) isolated from nature and characterized by having the ability to kill Streptococcus suis and having the genome represented by SEQ ID NO: 1, and a method for preventing and treating diseases caused by Streptococcus suis using the composition containing the Siphoviridae bacteriophage Str-SUP-3 as an active ingredient.
    Type: Application
    Filed: May 31, 2019
    Publication date: June 3, 2021
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Eun Ji Lee, Sang Hyeon Kang
  • Publication number: 20210161821
    Abstract: A freeze-dried formulation includes an antibacterial protein having killing activity specific to at least one of or all following species: Staphylococcus arlettae, Staphylococcus aureus, Staphylococcus auricularis, Staphylococcus carnosus, Staphylococcus carprae, Staphylococcus chromogenes, Staphylococcus cohnii, Staphylococcus delphini, Staphylococcus epidermidis, Staphylococcus equorum, Staphylococcus gallinarum, Staphylococcus hemolyticus, Staphylococcus hominis, Staphylococcus intermedius, Staphylococcus kloosii, Staphylococcus lentus, Staphylococcus lugdunensis, Staphylococcus muscae, Staphylococcus pasteuri, Staphylococcus saprophyticus, Staphylococcus warneri, and Staphylococcus xylosus; a poloxamer; a sugar, and an amino acid.
    Type: Application
    Filed: February 11, 2021
    Publication date: June 3, 2021
    Inventors: Seong Jun YOON, Soo Youn JUN, Gi Mo JUNG, Sang Hyeon KANG
  • Publication number: 20210163897
    Abstract: The present invention relates to a Siphoviridae bacteriophage Str-SUP-2 (Accession number: KCTC 13515BP) isolated from nature and characterized by having the ability to kill Streptococcus suis and having the genome represented by SEQ ID NO: 1, and a method for preventing and treating diseases caused by Streptococcus suis using the composition containing the Siphoviridae bacteriophage Str-SUP-2 as an active ingredient.
    Type: Application
    Filed: May 31, 2019
    Publication date: June 3, 2021
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Eun Ji Lee, Sang Hyeon Kang
  • Patent number: 11020442
    Abstract: The present invention relates to: Podoviridae bacteriophage Vib-PAP-2 (accession number KCTC 12910BP) which has the capability to specifically destroy Vibrio parahaemolyticus, is characterized by having a genome represented by SEQ ID NO: 1, and is isolated from nature; and a method for preventing and treating Vibrio parahaemolyticus infections, using a composition containing bacteriophage Vib-PAP-2 as an active ingredient.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: June 1, 2021
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Soon Hye Hwang, Sang Hyeon Kang
  • Publication number: 20210138005
    Abstract: The present invention relates to a Myoviridae bacteriophage Vib-PAP-7 (Accession number: KCTC 13247BP) isolated from nature, which has the ability to kill Vibrio parahaemolyticus and has the genome represented by SEQ ID NO: 1, and a method for preventing or treating a disease caused by Vibrio parahaemolyticus using a composition containing the Myoviridae bacteriophage Vib-PAP-7 as an active ingredient.
    Type: Application
    Filed: March 8, 2018
    Publication date: May 13, 2021
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Hyun Min Song, Eun Ji Lee, Sang Hyeon Kang
  • Publication number: 20210085733
    Abstract: The present invention relates to a Myoviridae bacteriophage Aer-HYP-3 (Accession number: KCTC 13479BP) isolated from nature, which has the ability to kill Aeromonas hydrophila bacteria and has the genome represented by SEQ ID NO: 1, and to a method of preventing and treating a disease caused by Aeromonas hydrophila bacteria using a composition containing the same as an active ingredient.
    Type: Application
    Filed: February 18, 2019
    Publication date: March 25, 2021
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Ji In Jung, Sang Hyeon Kang
  • Publication number: 20210070809
    Abstract: The present invention relates to an antibacterial protein EFAL-2 derived from bacteriophage Ent-FAP-4 (Accession number: KCTC 12854BP), which has the ability to kill Enterococcus faecium and an amino acid sequence represented by SEQ ID NO: 2, a pharmaceutical composition containing the same as an active ingredient, and a method for preventing or treating diseases caused by Enterococcus faecium using the pharmaceutical composition.
    Type: Application
    Filed: November 20, 2020
    Publication date: March 11, 2021
    Inventors: Seong Jun Yoon, Myung Soo Kang, Soo Youn Jun, Jong Hyun Kim, Gi Mo Jung, Jee Soo Son, Hyoun Rok Paik, Sang Hyeon Kang
  • Patent number: 10941172
    Abstract: Described is heme iron having Chemical Formula 1 not derived from porcine blood and a method of preparing the same, and more particularly to a method of chemically preparing heme iron having Chemical Formula 1 not derived from porcine blood, a method of preparing a salt thereof, and an iron supplement containing the salt thus prepared as an active ingredient:
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: March 9, 2021
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Jung In Pyo, Soon Hye Hwang, Soo Youn Jun, Sang Hyeon Kang
  • Publication number: 20210054345
    Abstract: The present invention relates to a Siphoviridae bacteriophage STP-2 (Accession number: KCTC 12853BP) isolated from nature and characterized by having the ability to destroy Salmonella Typhimurium and having a genome represented by SEQ ID NO:1; and to a method for preventing and treating diseases caused by Salmonella Typhimurium using Siphoviridae bacteriophage STP-2 containing the same as an active ingredient.
    Type: Application
    Filed: February 19, 2019
    Publication date: February 25, 2021
    Inventors: Seong Jun Yoon, Soo Youn Jun, Jee Soo Son, Hyoun Rok Paik, Beom Seok Kim, Sang Hyeon Kang
  • Patent number: 10898531
    Abstract: The present invention relates to a Myoviridae bacteriophage Vib-PAP-5 (accession number KCTC 13029BP) isolated from nature characterized by having a capability for specifically killing Vibrio parahaemolyticus bacteria and having a genome expressed by the SEQ ID NO:1, and to a method for preventing and treating infections from Vibrio parahaemolyticus bacteria by means of a composition comprising the Myoviridae bacteriophage Vib-PAP-5 as an active ingredient.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: January 26, 2021
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, An Sung Kwon
  • Patent number: 10894068
    Abstract: The present invention relates to a Podoviridae bacteriophage Bor-BRP-1 (accession no. KCTC 12705BP) isolated from nature, which has an ability to specifically kill Bordetella bronchiseptica bacteria and has a genome represented by SEQ ID NO: 1; and a method for preventing and treating infection with Bordetella bronchiseptica bacteria using a composition comprising the same as an active ingredient.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: January 19, 2021
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Suk Hwang Park, Byung Kuk Kim, Sang Hyeon Kang
  • Patent number: 10751377
    Abstract: The present invention relates to: Podoviridae bacteriophage Vib-PAP-1 (accession number KCTC 12817BP) which has the capability to specifically destroy Vibrio parahaemolyticus, is characterized by having a genome represented by SEQ ID NO: 1, and is isolated from nature; and a method for preventing and treating Vibrio parahaemolyticus infections, using a composition containing bacteriophage Vib-PAP-1 as an active ingredient.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: August 25, 2020
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Soon Hye Hwang, Sang Hyeon Kang
  • Patent number: 10722544
    Abstract: The present invention relates to a Siphoviridae bacteriophage Str-INP-1 (Accession NO: KCTC 12687BP) that is isolated from the nature and can kill specifically Streptococcus iniae cells, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1, and a method for preventing and treating the infections of Streptococcus iniae using the composition comprising said bacteriophage as an active ingredient.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: July 28, 2020
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Hyun Min Song, Sang Hyeon Kang
  • Patent number: 10696989
    Abstract: The present invention relates to heme iron not derived from porcine blood and a method of preparing the same, and more particularly to a method of biologically preparing heme iron not derived from porcine blood, a method of preparing a salt thereof, and an iron supplement containing the salt thus prepared as an active ingredient.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: June 30, 2020
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Jung In Pyo, Soon Hye Hwang, Soo Youn Jun, Sang Hyeon Kang
  • Patent number: 10568917
    Abstract: The present invention relates to: Myoviridae bacteriophage Pas-MUP-1 (accession number KCTC 12706BP) which has the capability to specifically destroy Pasteurella multocida, is characterized by having a genome represented by SEQ ID NO: 1, and is isolated from nature; and a method for preventing and treating Pasteurella multocida infections, using a composition containing bacteriophage Pas-MUP-1 as an active ingredient.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: February 25, 2020
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Dong Min Kang, Sang Hyeon Kang
  • Publication number: 20200054700
    Abstract: The present invention relates to Siphoviridae bacteriophage Ent-FAP-4 (accession number KCTC 12854BP), separated from nature, which is capable of specifically killing Enterococcus faecium and has a genome expressed by sequence number 1, a pharmaceutical composition, which comprises same as an active ingredient, and a method for preventing or treating diseases, induced by Enterococcus faecium, by means of the pharmaceutical composition.
    Type: Application
    Filed: January 11, 2018
    Publication date: February 20, 2020
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Sang Hyeon Kang
  • Publication number: 20200054042
    Abstract: The present invention relates to Siphoviridae bacteriophage Clo-PEP-2 (accession number KCTC 13185BP), separated from nature, which is capable of killing Clostridium perfringens and has a genome expressed by sequence number 1 and a method for preventing or treating diseases, induced by Clostridium perfringens, by means of a composition comprising the Siphoviridae bacteriophage Clo-PEP-2 as an active ingredient.
    Type: Application
    Filed: January 11, 2018
    Publication date: February 20, 2020
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Hee Jeong Shin, Sang Hyeon Kang
  • Publication number: 20200055902
    Abstract: The present invention relates to an antibacterial protein EFAL-2 derived from bacteriophage Ent-FAP-4 (deposition number KCTC 12854BP), a pharmaceutical composition including the same as an active ingredient, and a method for preventing or treating diseases caused by Enterococcus faecium by using the pharmaceutical composition, the antibacterial protein EFAL-2 being characterized by having the ability capable of killing Enterococcus faecium and having an amino acid sequence represented by SEQ ID NO: 2.
    Type: Application
    Filed: January 11, 2018
    Publication date: February 20, 2020
    Inventors: Seong Jun Yoon, Myung Soo Kang, Soo Youn Jun, Jong Hyun Kim, Gi Mo Jung, Jee Soo Son, Hyoun Rok Paik, Sang Hyeon Kang